triamcinolone hexacetonide + yttrium-90

Triamcinolone hexacetonide + yttrium-90 is a combination therapy used for intra-articular injection, primarily in the management of chronic inflammatory joint diseases such as rheumatoid arthritis. This combination leverages two distinct mechanisms: triamcinolone hexacetonide is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties, while yttrium-90 is a radioactive isotope used in radiosynoviorthesis to locally ablate inflamed synovial tissue. The rationale for combining these agents is to provide both immediate anti-inflammatory effects (from the corticosteroid) and longer-term reduction of synovial inflammation through targeted radiation (from yttrium-90). This approach has been studied particularly in large joints like the knee, especially when conventional therapies are insufficient[1][3]. However, clinical trials have not conclusively demonstrated that this combination offers significant advantages over either agent alone[1][3].